Seres Therapeutics Inc SER-287 Clinical Data Update Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Ulcerative Colitis Webcast. (Operator Instructions) I would now like to introduce your host for this conference call, Mr. Eric Shaff, CEO. You may begin.
Good morning, and welcome to Seres Therapeutics Ulcerative Colitis Investor Webcast. Thank you for spending time with us this morning. We will be reviewing slides alongside our remarks, and we have posted the presentation under the Investors and News section of the Seres website.
Our primary goal for today is to provide a better understanding and appreciation of our work to develop novel microbiome therapeutics for ulcerative colitis. We will be discussing our ongoing SER-287 ulcerative colitis Phase IIb study, with top line clinical results expected midyear, followed by additional data later this year. We will also be highlighting SER-301, our next-generation product candidate. We are excited about the prospects for both programs as potentially
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |